{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:25:12Z","timestamp":1740176712531,"version":"3.37.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Mrs Berta Kamprad foundation for exploration and combat cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","advancesradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.adro.2024.101531","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T08:22:47Z","timestamp":1714465367000},"page":"101531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume: A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-7150","authenticated-orcid":false,"given":"Elinore","family":"Wieslander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vilberg","family":"J\u00f3hannesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Kjell\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalsteinn","family":"Gunnlaugsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2024.101531_bib0001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0002","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0003","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0004","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0005","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2024.101531_bib0007","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0008","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year outcomes from PACE B: An international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) versus conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0009","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0360-3016(02)03011-0","article-title":"Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume?","volume":"54","author":"Kestin","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0010","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.juro.2010.12.059","article-title":"A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy","volume":"185","author":"Pierorazio","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2024.101531_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2024.101531_bib0013","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1097\/01.ju.0000121693.05077.3d","article-title":"Predicting the presence and side of extracapsular extension: A nomogram for staging prostate cancer","volume":"171","author":"Ohori","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2024.101531_bib0014","unstructured":"Sloan Kettering Cancer Center. Memorial. Accessed December 27, 2023. https:\/\/www.mskcc.org\/nomograms."},{"key":"10.1016\/j.adro.2024.101531_bib0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.urology.2015.06.003","article-title":"Multiparametric MRI improves accuracy of clinical nomograms for predicting extracapsular extension of prostate cancer","volume":"86","author":"Feng","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.adro.2024.101531_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112627","article-title":"International multi-site initiative to develop an MRI-inclusive nomogram for side-specific prediction of extraprostatic extension of prostate cancer","volume":"13","author":"Wibmer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.adro.2024.101531_bib0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2006.05.012","article-title":"Guidelines for primary radiotherapy of patients with prostate cancer","volume":"79","author":"Boehmer","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0018","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: A Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0019","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","article-title":"Radiation dose-volume effects in radiation-induced rectal injury","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0020","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2024.101531_bib0021","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0022","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): An international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2024.101531_bib0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.radonc.2022.02.002","article-title":"Seminal vesicle inter- and intra-fraction motion during radiotherapy for prostate cancer: A review","volume":"169","author":"Brand","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2024.101531_bib0024","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jmrs.457","article-title":"Proximal seminal vesicle displacement and margins for prostate cancer radiotherapy","volume":"68","author":"Lim Joon","year":"2021","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.adro.2024.101531_bib0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.meddos.2011.09.002","article-title":"Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer","volume":"37","author":"Stenmark","year":"2012","journal-title":"Med Dosim"},{"key":"10.1016\/j.adro.2024.101531_bib0026","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/clon.2002.0077","article-title":"A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to \u201cprostate alone\u201d","volume":"14","author":"Parker","year":"2002","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109424000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T18:26:38Z","timestamp":1726424798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109424000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2452109424000940"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2024.101531","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume: A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2024.101531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101531"}}